EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Enlicitide, a Novel Oral Macrocyclic Peptide PCSK9 Inhibitor for Lipid Lowering: A Systematic Review and Meta-Analysis

Burcu Yagmur iD, Elif Ijlal Cekirdekci iD

Journal of Cardiovascular Development and Disease · 20.08.2026 · 13 (8) · 398

DOI: 10.3390/jcdd13080398 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 20.08.2026. Verfasst von Burcu Yagmur und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University of Kyrenia, Kyrenia 99320, Cyprus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enlicitide (MK-0616) is an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for the treatment of hypercholesterolemia. We conducted the first systematic review and meta-analysis evaluating the efficacy and safety of enlicitide across randomized controlled trials enrolling adults with hypercholesterolemia or heterozygous familial hypercholesterolemia (HeFH). The primary outcome was the baseline-to-endpoint percentage change in low-density lipoprotein cholesterol (LDL-C); secondary outcomes included apolipoprotein B (ApoB), non-high-density lipoprotein cholesterol (non-HDL-C), lipoprotein(a) [Lp(a)], and safety. Four randomized controlled trials involving 3894 participants were included. Enlicitide achieved a substantial reduction in LDL-C (mean difference [MD]: −55.78 percentage points; 95% confidence interval [CI]: −61.15 to −50.42; p < 0.0001; I2 = 99.58%), with sustained efficacy demonstrated in the newly available 52-week Phase 3 CORALreef data. Significant reductions were also observed in ApoB (MD: −47.95 pp; 95% CI: −51.22 to −44.67), non-HDL-C (MD: −49.42 pp; 95% CI: −54.23 to −44.60), and Lp(a) (MD: −22.70 pp; 95% CI: −28.62 to −16.78). The pooled incidence of any adverse event was not statistically significant (event rate: 0.21; p = 0.087), and treatment discontinuation due to adverse events was uncommon (event rate: 0.007). Enlicitide demonstrated substantial lipid-lowering efficacy with an acceptable safety profile. The ongoing CORALreef Outcomes trial will determine whether these lipid improvements translate into reductions in major adverse cardiovascular events.

Schlagwörter

Stichwörter der Autor:innen

LDL-CMK-0616PCSK9 inhibitorenlicitidefamilial hypercholesterolemiameta-analysisoral lipid-lowering therapy

Autor:innen und Institutionen

  • Department of Cardiology, University of Kyrenia, Kyrenia 99320, Cyprus.

ORCID-Profile: Burcu Yagmur, Elif Ijlal Cekirdekci

Zitieren

APA

Yagmur, B., & Cekirdekci, E. I. (2026). Enlicitide, a Novel Oral Macrocyclic Peptide PCSK9 Inhibitor for Lipid Lowering: A Systematic Review and Meta-Analysis. Journal of Cardiovascular Development and Disease, 13(8), 398. https://doi.org/10.3390/jcdd13080398

Vancouver

Yagmur B, Cekirdekci EI. Enlicitide, a Novel Oral Macrocyclic Peptide PCSK9 Inhibitor for Lipid Lowering: A Systematic Review and Meta-Analysis. Journal of Cardiovascular Development and Disease. 2026;13(8):398. doi:10.3390/jcdd13080398

BibTeX
@article{Yagmur2026,
  author = {Yagmur, Burcu and Cekirdekci, Elif Ijlal},
  title = {Enlicitide, a Novel Oral Macrocyclic Peptide PCSK9 Inhibitor for Lipid Lowering: A Systematic Review and Meta-Analysis},
  journal = {Journal of Cardiovascular Development and Disease},
  year = {2026},
  volume = {13},
  number = {8},
  pages = {398},
  doi = {10.3390/jcdd13080398}
}
Kostenlos starten →